Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 16;11(3):921.
doi: 10.3390/biomedicines11030921.

Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review

Claudio Brasso  1 , Gianluca Colli  1 , Rodolfo Sgro  1 , Silvio Bellino  1 , Paola Bozzatello  1 , Cristiana Montemagni  1 , Vincenzo Villari  2 , Paola Rocca  1
Affiliations
Review

Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review

Claudio Brasso et al. Biomedicines. .

Abstract

Schizophrenia is among the fifteen most disabling diseases worldwide. Negative symptoms (NS) are highly prevalent in schizophrenia, negatively affect the functional outcome of the disorder, and their treatment is difficult and rarely specifically investigated. Serotonin-dopamine activity modulators (SDAMs), of which aripiprazole, cariprazine, brexpiprazole, and lumateperone were approved for schizophrenia treatment, represent a possible therapy to reduce NS. The aim of this rapid review is to summarize the evidence on this topic to make it readily available for psychiatrists treating NS and for further research. We searched the PubMed database for original studies using SDAM, aripiprazole, cariprazine, brexpiprazole, lumateperone, schizophrenia, and NS as keywords. We included four mega-analyses, eight meta-analyses, two post hoc analyses, and 20 clinical trials. Aripiprazole, cariprazine, and brexpiprazole were more effective than placebo in reducing NS. Only six studies compared SDAMs with other classes of antipsychotics, demonstrating a superiority in the treatment of NS mainly for cariprazine. The lack of specific research and various methodological issues, related to the study population and the assessment of NS, may have led to these partial results. Here, we highlight the need to conduct new methodologically robust investigations with head-to-head treatment comparisons and long-term observational studies on homogeneous groups of patients evaluating persistent NS with first- and second-generation scales, namely the Brief Negative Symptom Scale and the Clinical Assessment Interview for Negative Symptoms. This rapid review can expand research on NS therapeutic strategies in schizophrenia, which is fundamental for the long-term improvement of patients' quality of life.

Keywords: SDAMs; antipsychotic; aripiprazole; brexpiprazole; cariprazine; lumateperone; negative symptoms; schizophrenia; schizophrenia spectrum disorders; serotonin-dopamine activity modulators.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Selection flow-chart.
See this image and copyright information in PMC

References

    1. Charlson F.J., Ferrari A.J., Santomauro D.F., Diminic S., Stockings E., Scott J.G., McGrath J.J., Whiteford H.A. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr. Bull. 2018;44:1195–1203. doi: 10.1093/schbul/sby058. - DOI - PMC - PubMed
    1. Valiente C., Espinosa R., Trucharte A., Nieto J., Martínez-Prado L. The Challenge of Well-Being and Quality of Life: A Meta-Analysis of Psychological Interventions in Schizophrenia. Schizophr. Res. 2019;208:16–24. doi: 10.1016/j.schres.2019.01.040. - DOI - PubMed
    1. Andreasen N.C. The Lifetime Trajectory of Schizophrenia and the Concept of Neurodevelopment. Dialogues Clin. Neurosci. 2010;12:409–415. doi: 10.31887/DCNS.2010.12.3/nandreasen. - DOI - PMC - PubMed
    1. Ashe P.C., Berry M.D., Boulton A.A. Schizophrenia, a Neurodegenerative Disorder with Neurodevelopmental Antecedents. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2001;25:691–707. doi: 10.1016/S0278-5846(01)00159-2. - DOI - PubMed
    1. Buoli M., Serati M., Caldiroli A., Cremaschi L., Altamura A.C. Neurodevelopmental versus Neurodegenerative Model of Schizophrenia and Bipolar Disorder: Comparison with Physiological Brain Development and Aging. Psychiatr. Danub. 2017;29:24–27. doi: 10.24869/psyd.2017.24. - DOI - PubMed